Call for Specificity regarding Cancer Treatment to accelerate the Combination Antibody Therapy Market

Date : Sep 22, 2021 Author : PMR Editorial Staff Category : Healthcare

The last few years have witnessed renaissance with regards to continuous emphasis on developing cancer therapies targeted towards lesser side-effects. These targeted cancer therapies are known for fighting cancer cells with greater accuracy, i.e. they attack only the molecules essential for progression of tumor. This is how targeted cancer therapies stand out as compared to cytotoxic chemotherapies. This demand for specific course of treatment is likely to keep the hopes high for combination antibody therapy market.

As per the WHO, incidences of cancer are expected to increase three-fold in the next two decades. In this situation, combination antibody therapies are preferred as results could be obtained from minimal damage (abysmal damage to healthy cells).

Dispensability of Combination Antibody Therapy Market

The global combination antibody therapy market, by combination, states chemotherapy/antibody, antibody/antibody, conjugated antibodies, and bispecific antibodies. Application-wise, it’s blood cancer (myeloma, leukemia, and lymphoma), lung cancer, colorectal cancer, breast cancer, and likewise. End-user-wise, it’s cancer research institutes, hospitals, ASCs (Ambulatory Research Centres), and clinics.

Cardiovascular drug for disease is also being tried out in various combinations, as a part of research-based advancements. Persistence Market Research has given a detailed analysis of these facts with insights in its latest market study entitled “Combination Antibody Therapy Market”, wherein a section is exclusively reserved for cardiovascular drug for disease.

Geography-wise

North America holds the largest market share due to well-structured healthcare practices in the US and Canada. Europe stands second on this count. However, the Asia-Pacific is expected to grow at the fastest rate in the combination antibody therapy market in the forecast period due to the countries like Australia, South Korea, China, Japan, and India being at the forefront. Persistence Market Research has highlighted these nitty-gritties in its latest market study entitled “Combination Antibody Therapy Market”.

The Competitive Movement

The key players in combination antibody therapy market include Biogen Inc., Roche Holdings AG, Seattle Genetics Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Sanofi, Celgene Corp., Genmab A/S/, and others. Coming to developments, Amgen, September 2020, inked an agreement with Eli Lilly and Company for tabling combination antibody treatment for significantly increasing supply capacity for the latter’s potential Covid-19 therapies. On the other hand, Biogen, in collaboration with Eisai Co., Ltd., has developed Aducanumab for treating Alzheimer’s Disease (AD). Persistence market Research has sketched these facts and given the probable courses of action in its latest market study entitled “Combination Antibody Therapy market”.

In all, the global combination antibody therapy market is bound to make greater strides between 2021 and 2031 with innovative practices being followed on continuous basis – Persistence Market Research